FDA Approves Viome’s mRNA Technology and AI Platform for Detecting Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the early detection of oral and throat cancer through their proprietary mRNA technology in combination with Viome's next-gen AI platform. The first-of-its-kind tool screens...
Pfizer & BioNTech COVID-19 Vaccine Expected Approval From FDA for Younger Teens
Pfizer & BioNTech's COVID-19 vaccine is expected to receive FDA approval for adolescents ages 12 and older sometime this week. The expected approval comes from a Phase III trial in adolescents between the ages of 12 and 15 with 2,260 participants that demonstrated...
U.S. Patent Granted to Kemin Industries for Treatment of Human Immune Function
Kemin Industries has announced that the U.S. Patent and Trademark Office has granted the US 10,912,794 patent on the beta 1, 3 glucan for treating inflammation in the intestine and modulating human immune function. The patent approval comes after the US 9,574,217...
FDA Approves Chiesi Global Rare Diseases’ Ferriprox for Sickle Cell Disease
The U.S. Food and Drug Administration (FDA) approved Chiesi Global Rare Diseases' Ferriprox for treating transfusional iron overload which is caused by sickle cell disease (SCD). The treatment is approved in patients three years old and older, and expands the drug use...
Alzheimer’s Drug Shows Language Improvement for Fragile X Syndrome
A new study published in the Nature Medicine journal has shown that Tetra Therapeutics' Alzheimer's investigational disease drug improves language and learning ability in adults diagnosed with Fragile X Syndrome. Fragile X Syndrome is a genetic condition that causes...
Moderna Working on Improving COVID-19 Vaccine
Moderna, currently one of three companies granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, is continuing its efforts in improving the vaccine. Currently, the vaccine must be stored in cold temperatures;...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com